Idenix Pharmaceuticals Appoints Jacques Dumas, Ph.D., as Chief Scientific Officer
07 January 2014 - 12:00AM
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical
company engaged in the discovery and development of drugs for the
treatment of human viral diseases, today announced that it has
appointed Jacques Dumas, Ph.D., as its Executive Vice President and
Chief Scientific Officer. Dr. Dumas is trained as a medicinal
chemist and brings over 20 years of experience in pharmaceutical
discovery and development, supporting a variety of programs in
infectious diseases and oncology. He is a co-inventor of two
marketed drugs in the field of oncology, Nexavar® and Stivarga®.
His appointment will be effective January 20, 2014.
"Dr. Dumas brings a good complement of deep chemistry expertise
and overall business strategy to the Idenix team," said Ron Renaud,
President and Chief Executive Officer of Idenix. "His knowledge and
leadership will be important as we continue to conduct our
nucleotide prodrug discovery work in HCV as well as explore
potential therapeutic areas for which we can apply our chemistry
expertise. Additionally, as a native of France and a resident of
the Boston area, Jacques is an ideal fit to direct our talented
research teams in both Cambridge and Montpellier."
Dr. Dumas served as Vice President and Head of Strategy,
Infection Innovative Medicines at AstraZeneca plc since December
2010. In this position, he was responsible for disease area
strategy and external collaborations on behalf of AstraZeneca's
small-molecule infectious diseases unit. Prior to that role and
between February 2007 and December 2010, Dr. Dumas held the
successive positions of Associate Director, Medicinal Chemistry and
Emerging Products Director at AstraZeneca. Prior to joining
AstraZeneca, Dr. Dumas held several positions at Bayer HealthCare
Pharmaceuticals, Inc., a subsidiary of Bayer AG, from 1995 to 2007.
Dr. Dumas received his Ph.D. in Organic Chemistry from Paris 6
University in 1991.
ABOUT IDENIX
Idenix Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts, is a biopharmaceutical Company engaged in the
discovery and development of drugs for the treatment of human viral
diseases. Idenix's current focus is on the treatment of patients
with hepatitis C virus (HCV) infection. For further information
about Idenix, please refer to www.idenix.com.
Nexavar® and Stivarga® are registered trademarks of Bayer
HealthCare Pharmaceuticals, Inc. and Bayer, respectively.
CONTACT: Idenix Pharmaceuticals Contact:
Teri Dahlman, (617) 995-9807
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More News Articles